Good thing if all of us are health insured. There are lots of opportunities being one. Access on medicine is an important factor. Anyone that's invested heavily in IterMune Biopharmaceuticals should be pretty happy right now, as the FDA is going to review their drug Esbriet, which means it's into FDA trial phase, and if that means we may have a drug that will effectively treat idiopathic (meaning without a known cause) pulmonary fibrosis (scarring of the lungs) then it's definitely worth more than a <a rev=
Health Insurance
| ! ! ! |
Advertisement
Most Popular
- 10 Fabulous Freebies
- Get Your Share of Government Giveaways
- Save Money on Cable and Cell Bills
- 11 Ways to Find Extra Money NOW!
- 10 Insider Tips to Save Big at the Supermarket
- 11 Places to Find FREE Money!
- 12 Ways to Save Money on Life's Necessities
- 7 Steps to Boost Your Credit Score
- 11 Deductions to Save Big on Your Tax Bill
- Biggest Investing Lies You're Being Told
Survey Says
Advertisement
If you're paying for health and life insurance in your workplace, don't assume your plans are cheaper and better than what you'd find if you insured yourself. This isn't always the case.
Employees should always shop around before buying all the workplace benefits.
If you are older or not in the best of health, your employer's plan is most likely the best way to go, because you won't have to undergo any prior medical testing and you usually can't be excluded because of your health.
But young and older healthy workers may actually find better deals by shopping around on the internet. Check out www.insure.com, www.insweb.com and www.ehealth.com.
As for specialized policies, although sales of cancer and critical illness policies are growing, these policies are often too specific to be worth the money.
A good comprehensive policy should be enough for most employees.
Also, be sure to price term life insurance outside the company, before you sign up.
Good thing if all of us are health insured. There are lots of opportunities being one. Access on medicine is an important factor.Anyone that's invested heavily in IterMune Biopharmaceuticals should be pretty happy right now, as the FDA is going to review their drug Esbriet, which means it's into FDA trial phase, and if that means we may have a drug that will effectively treat idiopathic (meaning without a known cause) pulmonary fibrosis (scarring of the lungs) then it's definitely worth more than a payday loans worth to get the drug good to go. FDA approval is a big hurdle to clear, and FDA approved treatments mean big bucks for drug companies - and a cure of IPF is something that is worth the money to explore.



RSS
